Update and next steps for real-world translation of interventions for type 2 diabetes prevention: Reflections from a diabetes care editors' expert forum

Diabetes Care

Volumn 39, Issue 7, 2016, Pages 1186-1201

  Cefalu, William T ^a   Buse, John B ^b   Tuomilehto, Jaakko ^c   Alexander Fleming, G ^d   Ferrannini, Ele ^e   Gerstein, Hertzel C ^f   Bennett, Peter H ^g   Ramachandran, Ambady ^h   Raz, Itamar ⁱ   Rosenstock, Julio ^j   Kahn, Steven E ^k  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^d Kinexum   (United States)

^e INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^f HAMILTON HEALTH SCIENCES   (Canada)

^g NATIONAL INSTITUTES OF HEALTH   (United States)

^h Dr A Ramachandran's Diabetes Hospitals   (India)

ⁱ HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^j UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^k UNIVERSITY OF WASHINGTON   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; GLITAZONE DERIVATIVE; INSULIN GLARGINE; LIRAGLUTIDE; METFORMIN; NATEGLINIDE; PIOGLITAZONE; ROSIGLITAZONE; TETRAHYDROLIPSTATIN; TROGLITAZONE; VALSARTAN; VOGLIBOSE; ANTIDIABETIC AGENT;

CARDIOVASCULAR RISK; CLINICAL EFFECTIVENESS; CONSENSUS DEVELOPMENT; COST EFFECTIVENESS ANALYSIS; DIET THERAPY; DISEASE CLASSIFICATION; DISEASE DURATION; EVIDENCE BASED MEDICINE; EXERCISE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HEALTH PROMOTION; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; MEDICAL LITERATURE; MEDICAL RESEARCH; MEDICAL SOCIETY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PHYSICAL ACTIVITY; PREVENTIVE MEDICINE; REVIEW; RISK FACTOR; RISK REDUCTION; ADULT; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS, TYPE 2; GLUCOSE INTOLERANCE; LIFESTYLE; PREDIABETIC STATE;

ADULT; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; GLUCOSE INTOLERANCE; HUMANS; HYPOGLYCEMIC AGENTS; LIFE STYLE; METFORMIN; PREDIABETIC STATE;

EID: 84975883390     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc16-0873     Document Type: Review

References (139)

1. th ed. Available from www.diabetesatlas.org. Accessed 31 December 2015
2. Centers for Disease Control and Prevention. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014. Atlanta, GA, U.S. Department of Health and Human Services, 2014
3. Seuring T, Archangelidi O, Suhrcke M. The economic costs of type2 diabetes: aglobal systematic review. Pharmacoeconomics 2015;33:811-831
4. World Health Organization. Global Health Risks: Mortality and Burden of Disease Attributable to Selected Major Risks. Geneva, Switzerland, World Health Organization, 2009
5. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997;20: 537-544
6. Tuomilehto J, Lindström J, Eriksson JG, et al.; Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-1350
7. Knowler WC, Barrett-Connor E, Fowler SE, et al.; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metfor-min. N Engl J Med 2002;346:393-403
8. Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V; Indian Diabetes Prevention Programme. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevention type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 2006; 49:289-297
9. Ramachandran A, Snehalatha C, Mary S, et al. Pioglitazone doesnot enhance the effectiveness of lifestyle modification in preventing conversion of impaired glucose tolerance to diabetes in Asian Indians: results of the Indian Diabetes Prevention Programme-2 (IDPP-2). Diabetologia 2009; 52:1019-1026
10. DeFronzo RA, Tripathy D, Schwenke DC, et al.; ACT NOW Study. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med 2011;364:1104-1115
11. Saito T, Watanabe M, Nishida J, et al.; Zen-sharen Study for Prevention of Lifestyle Diseases Group. Lifestyle modification and prevention of type 2 diabetes in overweight Japanese with impaired fasting glucose levels: a randomized controlled trial. Arch Intern Med 2011;171: 1352-1360
12. Kosaka K, Noda M, Kuzuya T. Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Res Clin Pract 2005;67:152-162
13. Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic b-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes 2002;51:2796-2803
14. Gerstein HC, Yusuf S, Bosch J, et al.; DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006;368:1096-1105
15. Zinman B, Harris SB, Neuman J, et al. Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mel-litus (CANOE trial): a double-blind randomised controlled study. Lancet 2010;376:103-111
16. Gerstein HC, Bosch J, Dagenais GR, et al.; ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012;367:319-328
17. Chiasson J-L, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trial Research Group. Acarbose for prevention of type 2 diabetesmellitus:the STOP-NIDDM randomised trial. Lancet 2002;359:2072-2077
18. Kawamori R, Tajima N, Iwamoto Y, Kashiwagi A, Shimamoto K, Kaku K; Voglibose Ph-3 Study Group. Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet 2009;373:1607-1614
19. Holman RR, North BV, Tunbridge FK. Possible prevention of type 2 diabetes with acarbose or metformin. Diabetes 2000;49(Suppl. 1): A111
20. Holman RR, Haffner SM, McMurray JJ, et al.; NAVIGATOR Study Group. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 2010;362: 1463-1476
21. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004;27:155-161
22. Pi-Sunyer X, Astrup A, Fujioka K, et al.; SCALE Obesity and Prediabetes NN8022-1839 Study Group. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 2015;373:11-22
23. Albright AL, Gregg EW. Preventing type 2 diabetes in communities across the U.S.: the National Diabetes Prevention Program. Am J Prev Med 2013;44(Suppl. 4):S346-S351
24. U.S. Department of Health and Human Service. Independent experts confirm that diabetes prevention model supported by the Affordable Care Act saves money and improves health [Internet], 2016. Available from http://www.hhs.gov/about/news/2016/03/23/independent-experts-confirm-diabetes-prevention-model-supported-affordable-care-act-saves-money.html. Accessed 4 April 2016
25. Fradkin JE, Roberts BT, Rodgers GP. What's preventing us from preventing type 2 diabetes? N Engl J Med 2012;367:1177-1179
26. Kahn R, Davidson MB. The reality of type 2 diabetes prevention. Diabetes Care 2014;37: 943-949
27. Li G, Zhang P, Wang J, et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet 2008; 371:1783-1789
28. Li G, Zhang P, Wang J, et al. Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study. Lancet Diabetes Endocrinol 2014; 2:474-480
29. Gong Q, Gregg EW, Wang J, et al. Long-term effects of a randomised trial of a 6-year lifestyle intervention in impaired glucose tolerance on diabetes-related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia 2011;54:300-307
30. Lindström J, Louheranta A, Mannelin M, et al.; Finnish Diabetes Prevention Study Group. The Finnish Diabetes Prevention Study (DPS): lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care 2003;26: 3230-3236
31. Lindström J, Ilanne-Parikka P, Peltonen M, et al.; Finnish Diabetes Prevention Study Group. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 2006;368:1673-1679
32. Lindström J, Peltonen M, Eriksson JG, et al.; Finnish Diabetes Prevention Study (DPS). Improved lifestyle and decreased diabetes risk over 13 years: long-term follow-up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia 2013;56:284-293
33. Knowler WC, Hamman RF, Edelstein SL, et al.; Diabetes Prevention Program Research Group. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 2005;54:1150-1156
34. Knowler WC, Fowler SE, Hamman RF, et al.; Diabetes Prevention Program Research Group. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009;374:1677-1686
35. Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. Lancet Diabetes Endocrinol 2015;3:866-875
36. Herman WH, Hoerger TJ, Brandle M, et al.; Diabetes Prevention Program Research Group. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med 2005;142:323-332
37. Snehalatha C, Mary S, Joshi VV, Ramachandran A. Beneficial effects of strategies for primary prevention of diabetes on cardiovascular risk factors: results of the Indian Diabetes Prevention Programme. Diab Vasc Dis Res 2008;5:25-29
38. Gerstein HC, Mohan V, Avezum A, et al.; DREAM On (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication Ongoing Follow-up) Investigators. Long-term effect of rosiglitazone and/or ramipril on the incidence of diabetes. Diabetologia 2011;54: 487-495
39. DeFronzo RA, Abdul-Ghani M. Type 2 diabetes can be prevented with early pharmacological intervention. Diabetes Care 2011;34(Suppl. 2): S202-S209
40. Gerstein H, Yusuf S, Riddle MC, Ryden L, Bosch J; ORIGIN Trial Investigators. Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glar-gine Intervention). Am Heart J 2008;155:26-32, 32.e1-32.e6
41. ORIGIN Trial Investigators. Cardiovascular and other outcomes postintervention with insulin glargine and omega-3 fatty acids (ORIGINALE). Diabetes Care 2016;39:709-716
42. Holman RR, Blackwell L, Stratton IM, Manley SE, Tucker L, Frighi V. Six-year results from the Early Diabetes Intervention Trial. Dia-bet Med 2003;20(Suppl. 2):15
43. Tabák AG, Herder C, Rathmann W, Brunner EJ, Kivimäki M. Prediabetes: a high-risk state for diabetes development. Lancet 2012;379:2279-2290
44. Abdul-Ghani MA, Tripathy D, DeFronzo RA. Contributions of b-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care 2006;29:1130-1139
45. American Diabetes Association. Classification and diagnosis of diabetes. Sec. 2. In Standards of Medical Care in Diabetesd2016. Diabetes Care 2016;39(Suppl. 1):S13-S22
46. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979;28:1039-1057
47. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-1197
48. Genuth S, Alberti KG, Bennett P, et al.; Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003;26:3160-3167
49. World Health Organization. Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia: Report of a WHO/IDF Consultation. Geneva, Switzerland, World Health Organization, 2006
50. International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 2009;32:1327-1334
51. World Health Organization. Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus: Abbreviated Report of a WHO Consultation. Geneva, Switzerland, World Health Organization, 2011
52. World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications: Report of a WHO Consultation. Part 1. Diagnosis and Classification of Diabetes Mellitus. Geneva, Switzerland, World Health Organization, 1999
53. National Institute for Health and Clinical Excellence. Preventing Type 2 Diabetes: Risk Identification and Interventions for Individuals at High Risk. NICE Public Health Guidance 38. Manchester, U.K., National Institute for Health and Clinical Excellence, 2012
54. 1c 6.0-6.4% and other prediabetes definitions to type 2 diabetes: a meta-analysis. Diabetologia 2013;56:1489-1493
55. James C, Bullard KM, Rolka DB, et al. Implications of alternative definitions of prediabetes for prevalence in U.S. Adults. Diabetes Care 2011;34:387-391
56. Plantinga LC, Crews DC, Coresh J, et al.; CDC CKD Surveillance Team. Prevalence of chronic kidney disease in US adults with undiagnosed diabetes or prediabetes. Clin J Am Soc Nephrol 2010;5:673-682
57. Tesfaye S, Boulton AJ, Dyck PJ, et al.; Toronto Diabetic Neuropathy Expert Group. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 2010;33:2285-2293
58. Wu JS, Yang YC, Lin TS, et al. Epidemiolog-ical evidence of altered cardiac autonomic function in subjects with impaired glucose tolerance but not isolated impaired fasting glucose. J Clin Endocrinol Metab 2007;92:3885-3889
59. Schroeder EB, Chambless LE, Liao D, et al.; Atherosclerosis Risk in Communities (ARIC) study. Diabetes, glucose, insulin, and heart rate variability: the Atherosclerosis Risk in Communities (ARIC) study. Diabetes Care 2005;28: 668-674
60. Gerstein HC, Santaguida P, Raina P, et al. Annual incidence and relative risk of diabetes in people with various categories of dysglyce-mia: asystematic overview and meta-analysis of prospective studies. Diabetes Res Clin Pract 2007;78:305-312
61. Forouhi NG, Luan J, Hennings S, Wareham NJ. Incidence of type 2 diabetes in England and its association with baseline impaired fasting glucose: the Ely study 1990-2000. Diabet Med 2007;24:200-207
62. Anjana RM, Shanthi Rani CS, Deepa M, et al. Incidence of diabetes and prediabetes and predictors of progression among Asian Indians: 10-year follow-up of the Chennai Urban Rural Epidemiology Study (CURES). Diabetes Care 2015;38:1441-1448
63. Tirosh A, Shai I, Tekes-Manova D, et al.; Israeli Diabetes Research Group. Normal fasting plasma glucose levels and type 2 diabetes in young men. N Engl J Med 2005;353:1454-1462
64. Yeboah J, Bertoni AG, Herrington DM, Post WS, Burke GL. Impaired fasting glucose and the risk of incident diabetes mellitus and cardiovascular events in an adult population: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol 2011;58:140-146
65. Seshasai SR, Kaptoge S, Thompson A, et al.; Emerging Risk Factors Collaboration. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011;364:829-841
66. Xu T, Liu W, Cai X, et al. Risk of coronary heart disease in different criterion of impaired fasting glucose: a meta-analysis. Medicine 2015; 94:e1740
67. Ning F, Zhang L, Dekker JM, et al.; DECODE Finnish and Swedish Study Investigators. Development of coronary heart disease and ischemic stroke in relation to fasting and 2-hour plasma glucose levels in the normal range. Cardiovasc Diabetol 2012;11:76
68. Jackson SL, Long Q, Rhee MK, et al. Weight loss and incidence of diabetes withthe Veterans Health Administration MOVE! lifestyle change programme: an observational study. Lancet Diabetes Endocrinol 2015;3:173-180
69. Mau MK, Keawe'aimoku Kaholokula J, West MR, et al. Translating diabetes prevention into native Hawaiian and Pacific Islander communities: the PILI 'Ohana Pilot project. Prog Community Health Partnersh 2010;4:7-16
70. Pagoto SL, Kantor L, Bodenlos JS, Gitkind M, Ma Y. Translating the diabetes prevention program into a hospital-based weightloss program. Health Psychol 2008;27(Suppl.):S91-S98
71. Seidel MC, Powell RO, Zgibor JC, Siminerio LM, Piatt GA. Translating the Diabetes Prevention Program into an urban medically under-served community: a nonrandomized prospective intervention study. Diabetes Care 2008;31:684-689
72. Boltri JM, Davis-Smith YM, Seale JP, Shellenberger S, Okosun IS, Cornelius ME. Diabetes prevention in a faith-based setting: results of translational research. J Public Health Manag Pract 2008;14:29-32
73. Aldana SG, Barlow M, Smith R, et al. The Diabetes Prevention Program: a worksite experience. AAOHN J 2005;53:499-505; quiz 506-507
74. Whittemore R, Melkus G, Wagner J, Dziura J, Northrup V, Grey M. Translating the Diabetes Prevention Program to primary care: a pilot study. Nurs Res 2009;58:2-12
75. Block G, Azar KM, Romanelli RJ, et al. Diabetes prevention and weight loss with a fully automated behavioral intervention by email, web, and mobile phone: a randomized controlled trial among persons with prediabetes. J Med Internet Res 2015;17:e240
76. Ramachandran A, Snehalatha C, Ram J, et al. Effectiveness of mobile phone messaging in prevention of type 2 diabetes by lifestyle modification in men in India: a prospective, parallel-group, randomised controlled trial. Lancet Diabetes Endocrinol 2013;1:191-198
77. Saaristo T, Peltonen M, Keinänen-Kiukaanniemi S, et al.; FIN-D2D Study Group. National type 2 diabetes prevention programme in Finland: FIN-D2D. Int J Circumpolar Health 2007;66:101-112
78. Dunbar JA, Jayawardena A, Johnson G, et al. Scaling up diabetes prevention in Victoria, Australia: policy development, implementation, and evaluation. Diabetes Care 2014;37:934-942
79. Sakane N, Sato J, Tsushita K, et al.; Japan Diabetes Prevention Program (JDPP) Research Group. Prevention of type 2 diabetes in a primary healthcare setting: three-year results of lifestyle intervention in Japanese subjects with impaired glucose tolerance. BMC Public Health 2011;11:40
80. Wareham NJ. Mind the gap: efficacy versus effectiveness of lifestyle interventions to prevent diabetes. Lancet Diabetes Endocrinol 2015;3:160-161
81. Li G, Hu Y, Yang W, et al.; DA Qing IGT and Diabetes Study. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes melli-tus: the DA Qing IGT and Diabetes Study. Diabetes Res Clin Pract 2002;58:193-200
82. Lindström J, Tuomilehto J. The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabetes Care 2003;26:725-731
83. Lindström J, Peltonen M, Eriksson JG, et al.; Finnish Diabetes Prevention Study (DPS) Group. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care 2008;31:857-862
84. de Mello VDF, Lindström J, Eriksson J, et al. Insulin secretion and its determinants in the progression of impaired glucose tolerance to type 2 diabetes in impaired glucose-tolerant individuals: the Finnish Diabetes Prevention Study. Diabetes Care 2012;35:211-217
85. Tuomilehto H, Peltonen M, Partinen M, et al.; Finnish Diabetes Prevention Study Group. Sleep duration, lifestyle intervention, and incidence of type 2 diabetes in impaired glucose tolerance: The Finnish Diabetes Prevention Study. Diabetes Care 2009;32:1965-1971
86. Wang J, Kuusisto J, Vänttinen M, et al. Variants of transcription factor 7-like 2 (TCF7L2) gene predict conversion to type 2 diabetes in the Finnish Diabetes Prevention Study and are associated with impaired glucose regulation and impaired insulin secretion. Diabetologia 2007;50:1192-1200
87. Siitonen N, Lindström J, Eriksson J, et al. Association between a deletion/insertion polymorphism in the a2B-adrenergic receptor gene and insulin secretion and type 2 diabetes. The Finnish Diabetes Prevention Study. Diabetolo-gia 2004;47:1416-1424
88. Laaksonen DE, Siitonen N, Lindström J, et al.; Finnish Diabetes Prevention Study Group. Physical activity, diet, and incident diabetes in relation to an ADRA2B polymorphism. Med Sci Sports Exerc 2007;39:227-232
89. Uusitupa MI, Stancáková A, Peltonen M, et al. Impact of positive family history and genetic risk variants on the incidence of diabetes: the Finnish Diabetes Prevention Study. Diabetes Care 2011;34:418-423
90. Kitabchi AE, Temprosa M, Knowler WC, et al.; Diabetes Prevention Program Research Group. Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin. Diabetes 2005;54: 2404-2414
91. Aroda VR, Christophi CA, Edelstein SL, et al.; Diabetes Prevention Program Research Group. The effect of lifestyle intervention and metfor-min on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10-year follow-up. J Clin Endocrinol Metab 2015;100:1646-1653
92. Florez JC, Jablonski KA, Bayley N, et al.; Diabetes Prevention Program Research Group. TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med 2006;355:241-250
93. Dabelea D, Ma Y, Knowler WC, et al.; Diabetes Prevention Program Research Group. Diabetes autoantibodies do not predict progression to diabetes in adults: the Diabetes Prevention Program. Diabet Med 2014;31: 1064-1068
94. Perreault L, Pan Q, Mather KJ, Watson KE, Hamman RF, Kahn SE; Diabetes Prevention Program Research Group. Regression from pre-diabetes to normal glucose regulation is associated with long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. Lancet 2012;379:2243-2251
95. Ramachandran A, Snehalatha C, Samith Shetty A, Nanditha A. Predictive value of HbA1c for incident diabetes among subjects with impaired glucose tolerance-analysis of the Indian Diabetes Prevention Programmes. Diabet Med 2012;29:94-98
96. Nanditha A, Ram J, Snehalatha C, et al. Early improvement predicts reduced risk of incident diabetes and improved cardiovascular risk in prediabetic Asian Indian men participating in a 2-year lifestyle intervention program. Diabetes Care 2014;37:3009-3015
97. Ram J, Snehalatha C, Selvam S, et al. The oral disposition index is a strong predictor of incident diabetes in Asian Indian prediabetic men. Acta Diabetol 2015;52:733-741
98. Siu AL; U S Preventive Services Task Force. Screening for abnormal blood glucose and type 2 diabetes mellitus: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2015;163:861-868
99. Congress.gov. H.R.2102: Medicare Diabetes Prevention Act of 2015 [Internet]. Available from https://www.congress.gov/bill/114th-congress/house-bill/2102. Accessed 6 November 2015
100. Patient-Centered Outcomes Research Institute. Future Research Prioritization: Comparative Effectiveness of Strategies for Diabetes Prevention and Prediabetes [Internet], July 2015. Available from http://www.pcori.org/sites/default/files/PCORI-Assessment-Options-AP-Meeting-Topic-1-Brief-CER-Prevention-Pre-Diabetes-07-09-10-2015.pdf. Accessed 6 November 2015
101. Ackermann RT, Kenrik Duru O, Albu JB, et al.; NEXT-D Study Group. Evaluating diabetes health policies using natural experiments: the natural experiments for translation in diabetes study. Am J Prev Med 2015;48:747-754
102. Thorpe KE. Analysis & commentary: the Affordable Care Act lays the groundwork for a national diabetes prevention and treatment strategy. Health Aff (Millwood) 2012;31:61-66
103. Community Preventive Services Task Force. Diabetes prevention and control: combined diet and physical activity promotion programs to prevent type 2 diabetes among people at increased risk: task force finding and rationale statement [Internet]. Available from http://www.thecommunityguide.org/diabetes/supportingmaterials/RRcombineddietandpa.html. Accessed 6 November 2015
104. Phung OJ, Sood NA, Sill BE, Coleman CI. Oral anti-diabetic drugs for the prevention of Type 2 diabetes. Diabet Med 2011;28:948-964
105. DeFronzo RA, Abdul-Ghani MA. Preservation of b-cell function: the key to diabetes prevention. J Clin Endocrinol Metab 2011;96:2354-2366
106. Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myo-cardial infarction and cardiovascular mortality. Arch Intern Med 2010;170:1191-1201
107. Astrup A, Carraro R, Finer N, et al. NN8022-1807 Investigators. Safety, tolerability, and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes 2012;36:843-854
108. RISE Consortium. Restoring Insulin Secretion (RISE): design of studies of b-cell preservation in prediabetes and early type 2 diabetes across the life span. Diabetes Care 2014;37: 780-788
109. Diabetes Prevention Program Research Group. Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care 2012;35:731-737
110. Diabetes Prevention Program Research Group. The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS. Diabetes Care 2012;35:723-730
111. Ratner RE, Christophi CA, Metzger BE, et al.; Diabetes Prevention Program Research Group. Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions. J Clin Endocrinol Metab 2008;93:4774-4779
112. Sussman JB, Kent DM, Nelson JP, Hayward RA. Improving diabetes prevention with benefit based tailored treatment: risk based reanalysis of Diabetes Prevention Program. BMJ 2015;350: h454
113. American Diabetes Association. Prevention or delay of type 2 diabetes. Sec. 4. In Standards of Medical Care in Diabetesd2016. Diabetes Care 2016;39(Suppl. 1):S36-S38
114. Moin T, Li J, Duru OK, et al. Metformin prescription for insured adults with prediabetes from 2010 to 2012: a retrospective cohort study. Ann Intern Med 2015;162:542-548
115. Hanefeld M, Schaper F. Acarbose: oral anti-diabetes drug with additional cardiovascular benefits. Expert Rev Cardiovasc Ther 2008;6:153-163
116. U.S. Food and Drug Administration. Guidance for Industry: Diabetes Mellitus: Developing Drugs and Therapeutic Biologics for Treatment and Prevention [Draft Guidance] [Internet], February 2008. Available from http://www.fda.gov/downloads/Drugs/GuidanceCompliance RegulatoryInformation/Guidances/UCM071624.pdf. Accessed 12 November 2015
117. Gerstein HC. Point: If it is important to prevent type 2 diabetes, it is important to consider all proven therapies within a comprehensive approach. Diabetes Care 2007;30:432-434
118. Palmer JP, Fleming GA, Greenbaum CJ, et al. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve b-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes 2004;53: 250-264
119. U.S. Food and Drug Administration. FDA approves new indication for Crestor [Internet].Avail-able from http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm200128.htm. Accessed 17 February 2016
120. Aroda VR, Edelstein SL, Goldberg RB, et al.; Diabetes Prevention Program Research Group. Long-term metformin use and vitamin B12 deficiency in the Diabetes Prevention Program Outcomes Study. J Clin Endocrinol Metab 2016;101:1754-1761
121. Alssema M, Vistisen D, Heymans MW, et al.; DETECT-2 collaboration. The Evaluation of Screening and Early Detection Strategies for Type 2 Diabetes and Impaired Glucose Tolerance (DETECT-2) update of the Finnish diabetes risk score for prediction of incident type 2 diabetes. Diabetologia 2011;54:1004-1012
122. American Diabetes Association. Type 2 diabetes risk test [Internet]. Available from http://www.diabetes.org/are-you-at-risk/diabetes-risk-test/?loc=atrisk-slabnav. Accessed 17 January 2016
123. Diabetes UK.Diabetesrisk score assessment tool [Internet]. Available from https://www.diabetes.org.uk/professionals/diabetes-risk-score-assessment-tool. Accessed 17 January 2016
124. Chen L, Magliano DJ, Balkau B, et al. AUSDRISK: an Australian type 2 diabetes risk assessment tool based on demographic, lifestyle and simple anthropometric measures. Med J Aust 2010;192:197-202
125. Mohan V, Deepa R, Deepa M, Somannavar S, Datta M. A simplified Indian diabetes risk score for screening for undiagnosed diabetic subjects. J Assoc Physicians India 2005;53:759-763
126. Jiang L, Manson SM, Beals J, et al.; Special Diabetes Program for Indians Diabetes Prevention Demonstration Project. Translating the Diabetes Prevention Program into American Indian and Alaska Native communities: results from the Special Diabetes Program for Indians Diabetes Prevention demonstration project. Diabetes Care 2013;36:2027-2034
127. Ackermann RT, Finch EA, Brizendine E, Zhou H, Marrero DG. Translating the Diabetes Prevention Program into the community: the DEPLOY pilot study. Am J Prev Med 2008;35:357-363
128. Lipscomb ER, Finch EA, Brizendine E, Saha CK, Hays LM, Ackermann RT. Reduced 10-year risk of coronary heart disease in patients who participated in a community-based diabetes prevention program: the DEPLOY pilot study. Diabetes Care 2009;32:394-396
129. YMCA. Measureable progress, unlimited support: Diabetes Prevention Program fact sheet [Internet], December 2015. Available from http://www.ymca.net/diabetes-prevention/statistics.html. Accessed 21 December 2015
130. Prasad VM. Using mobile technology for health [Internet]. Available from http://www.searo.who.int/entity/noncommunicable-diseases/events/ncd-bengaluru-mobile-technology-for-health.pdf. Accessed 17 December 2015
131. Finnish Diabetes Association. Implementation of type 2 diabetes prevention plan: project plan 2003-2007, FIN-D2D project [Internet]. Available from http://www.diabetes.fi/files/1107/Implementation-of-Type-2-Diabetes-Prevention.- Project-Plan-2003-2007.pdf. Accessed 18 December 2015
132. Saaristo T, Moilanen L, Korpi-Hyövälti E, et al. Lifestyle intervention for prevention of type 2 diabetes in primary health care: one-year follow-up of the Finnish National Diabetes Prevention Program (FIN-D2D). Diabetes Care 2010;33:2146-2151
133. Schwarz PE, Lindström J, Kissimova-Scarbeck K, et al.; DE-PLAN project. The European perspective of type 2 diabetes prevention: diabetes in Europe-prevention using lifestyle, physical activity and nutritional intervention (DE-PLAN) project. Exp Clin Endocrinol Diabetes 2008;116:167-172
134. Lindström J, Neumann A, Sheppard KE, et al. Take action to prevent diabetes-the IMAGE toolkit for the prevention of type 2 diabetes in Europe. Horm Metab Res 2010; 42(Suppl. 1):S37-S55
135. Nanditha A, Ma RCW, Ramachandran A, et al. Diabetes in Asia and the Pacific: implications for the global epidemic. Diabetes Care 2016;39:472-485
136. Singapore Health Promotion Board. Pre-diabetes intervention programme [Internet]. Available from http://www.hpb.gov.sg/HOPPortal/programmes-article/5844. Accessed 18 December 2015
137. Singapore Health Promotion Board. Healthier dining programme [Internet]. Available from http://www.hpb.gov.sg/HOPPortal/programmes-article/HPB063209. Accessed 3 March 2016
138. Singapore Health Promotion Board. Workplace health promotion [Internet]. Available from http://www.hpb.gov.sg/HOPPortal/programmes-article/5568. Accessed 3 March 2016
139. Neudorfer Y. Impact investing in Israel. Presentation to the G8 Impact Investment Task-force. 9 July 2015 [Internet]. Available from http://www.socialimpactinvestment.org/reports/Impact-Investment-in-Israel-Yaron-Neudorfer.pptx. Accessed 3 March 2016